Navigation Links
Funding for Orphan Disease Indication Will Compare EpiVax's Tregitope with IVIG
Date:11/16/2012

PROVIDENCE, R.I., Nov. 16, 2012 /PRNewswire/ -- Full Article Here

(Logo:  http://photos.prnewswire.com/prnh/20121116/NE15175LOGO )

Providence-based biotech company EpiVax, Inc. was awarded a new $55,000 grant from the GBS-CIDP Foundation International, to explore using Tregitopes as a novel immuno-modulator therapy for a nerve disease that is currently treated with intravenous immunoglobulin G (IVIG). This award and the recent addition of an SBIR grant for $600,000 to explore the use of Tregitope for Pompe disease (August 2012) will bring the total amount of funding awarded to EpiVax for research and development of Tregitopes to $3.4M in 2012. The surge in funding will result in expansion at the Providence-based biotech company, that is working on spinning off the Tregitope technology into a new venture or angel-backed company.

The GBS-CIDP Foundation research funds will be devoted to developing a safer, more effective replacement for IVIG in the treatment of patients with CIDP (Chronic Inflammatory Demyelinating Polyneuropathy). CIDP patients develop a debilitating nerve condition that requires treatment with IVIG. A single dose of IVIG costs $8,000, and patients often spend tens of thousands of dollars obtaining treatment per year. Alternative treatments that might redirect the immune response toward antigen-specific tolerance without immunosuppressive agents are needed.

The company has been extremely successful in SBIR funding for the Tregitope endeavor despite the constrained funding environment. SBIR grants awarded to EpiVax this year include a Phase I for testing the ability for Tregitopes to reduce inhibitors to FVIII, a separate Phase I SBIR for testing the ability of Tregitopes to reduce immune responses to GAA, a protein that is deficient in Pompe's disease, and a Phase II award to perform safety, toxicity and formulation studies on Tregitopes in the NOD model of Type 1 Diabetes.

About Tregitopes

Tregitopes are linear sequences of peptides contained within the framework of monoclonal antibodies and immunoglobulin-G ,which activate natural regulatory T cells. Tregitopes act as a natural 'off switch' and have been shown in standard preclinical models, and by collaborating laboratories, to suppress and treat autoimmune disease, allergies, and to effectively suppress the immunogenicity of co-administered proteins. This is a natural mechanism for suppressing tissue-destroying immune cells that are the root cause of 'organ-specific autoimmune diseases', in addition, modifying immune responses to biotherapeutics (such as FVIII and other biologics).

Tregitopes were discovered by the team of Anne S. De Groot and Bill Martin at EpiVax.

www.EpiVax.com

CONTACT:  Anthony Marcello, +1-401-272-2123, amarcello@epivax.com


'/>"/>
SOURCE EpiVax, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
2. Research and education success earns more NSF funding
3. Auxogyn Completes $20 Million In Series A Funding
4. NeuroPhage Receives Michael J. Fox Foundation Funding for Parkinsons Disease Research
5. AquaLiv Technologies, Inc. and Its Subsidiary, AquaLiv, Inc., Release Funding Updates
6. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
7. U.S. Senate Urged to Increase Federal Funding for Research into Hereditary Angioedema, a Rare and Serious Genetic Disorder
8. Glythera Relocates to North East as Part of £2M Funding Round
9. Funding boost for silicon carbide super chip
10. Laboratory Decision Makers Cautiously Optimistic about Funding Conditions, Finds Frost & Sullivan
11. Heartland Plant Innovations Wins Kansas Bioscience Authority Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... USA, and CARDIFF, UK (PRWEB) , ... June 23, 2017 , ... ... (LANL), and Brian Lula, president of Physik Instrumente USA, have been selected as this ... and photonics . , The two have been invited along with other honorees to ...
(Date:6/22/2017)... ... ... Building on the success of the inaugural RAADfest last year, RAADfest 2017 ... in radical life extension. RAADfest combines cutting edge science presented for a lay audience, ... making it the largest most comprehensive and inclusive super longevity event in the world. ...
(Date:6/22/2017)... Linda, Ca (PRWEB) , ... June 22, 2017 , ... ... worldwide. It took 20 years until the first data on cross-contamination of human cell ... lines has been an increasing issue in cell culture labs and is associated with ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... determine the adulterants which pose the most likely threat to their products at ... this year. , IFT's annual food expo attracts over 20,000 attendees representing ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):